EUVIMEDEUVIMED entdecken
Crossref

The impact of brain metastasis and other factors on overall survival in patients with metastatic non-small cell lung cancer

Abdurrahman Biçer, Mehmet Maruf Kayran, Muslih Ürün

Cancer Plus · 09.03.2026 · 8 (2) · 025480079

DOI: 10.36922/cp025480079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Plus, online erschienen am 09.03.2026. Verfasst von Abdurrahman Biçer und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain metastases are common in metastatic non-small cell lung cancer (NSCLC) and portend poor outcomes, yet prognostic determinants—particularly whether brain metastases are present at diagnosis or develop during follow-up—remain incompletely characterized in driver-negative patients treated with first-line platinum-based doublet chemotherapy. This retrospective study evaluated prognostic factors affecting overall survival (OS) in patients with metastatic NSCLC who had brain metastases at diagnosis or developed them during follow-up and received first-line platinum-based doublet chemotherapy. A total of 136 epidermal growth factor receptor (EGFR)-, anaplastic lymphoma kinase (ALK)-, and c-ros oncogene-1 (ROS-1)-negative patients from a single center were included to identify key demographic, clinical, and treatment-related predictors of survival. Multivariate analysis showed that male sex (hazard ratio [HR]: 2.070), higher Eastern Cooperative Oncology Group (ECOG) performance status (HR: 1.438), presence of multiple metastatic sites (HR: 1.297), and lack of response to first-line chemotherapy (HR: 1.579) were independently associated with worse OS. Conversely, a higher number of chemotherapy cycles was a favorable prognostic factor (HR: 0.797). The timing of brain metastasis, whether present at diagnosis or occurring during follow-up, was not significantly associated with OS. Median OS for the entire cohort was 11.8 months. Females had longer survival than males (21.2 vs. 9.8 months), and patients receiving second-line therapy had improved survival compared with those who did not (24.2 vs. 8.3 months). Survival in this population appears to be primarily influenced by sex, performance status, metastatic burden, and treatment response rather than the timing of brain metastasis.  These findings emphasize the importance of individualized treatment strategies, early response assessment, and access to subsequent therapy.

Zitieren

APA

Biçer, A., Kayran, M. M., & Ürün, M. (2026). The impact of brain metastasis and other factors on overall survival in patients with metastatic non-small cell lung cancer. Cancer Plus, 8(2), 025480079. https://doi.org/10.36922/cp025480079

Vancouver

Biçer A, Kayran MM, Ürün M. The impact of brain metastasis and other factors on overall survival in patients with metastatic non-small cell lung cancer. Cancer Plus. 2026;8(2):025480079. doi:10.36922/cp025480079

BibTeX
@article{Bier2026,
  author = {Biçer, Abdurrahman and Kayran, Mehmet Maruf and Ürün, Muslih},
  title = {The impact of brain metastasis and other factors on overall survival in patients with metastatic non-small cell lung cancer},
  journal = {Cancer Plus},
  year = {2026},
  volume = {8},
  number = {2},
  pages = {025480079},
  doi = {10.36922/cp025480079}
}
Kostenlos starten →